Tocagen (TOCA) Competitors

Zymeworks (NYSE:ZYME) and Tocagen (NASDAQ:TOCA) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, community ranking, profitability, valuation, institutional ownership, risk, dividends, earnings and analyst recommendations.

Do analysts rate ZYME or TOCA?

Zymeworks currently has a consensus price target of $21.00, indicating a potential upside of 65.75%. Given Zymeworks' stronger consensus rating and higher probable upside, research analysts clearly believe Zymeworks is more favorable than Tocagen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zymeworks	0 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.90
Tocagen	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Does the media refer more to ZYME or TOCA?

In the previous week, Zymeworks had 3 more articles in the media than Tocagen. MarketBeat recorded 3 mentions for Zymeworks and 0 mentions for Tocagen. Zymeworks' average media sentiment score of 1.47 beat Tocagen's score of 0.00 indicating that Zymeworks is being referred to more favorably in the media.

Company	Overall Sentiment
Zymeworks	Positive
Tocagen	Neutral

Which has higher earnings & valuation, ZYME or TOCA?

Tocagen has lower revenue, but higher earnings than Zymeworks. Zymeworks is trading at a lower price-to-earnings ratio than Tocagen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zymeworks	$93.38M	9.44	-$118.67M	-$1.49	-8.50
Tocagen	$40K	7,226.53	-$63.52M	-$2.69	-4.49

Is ZYME or TOCA more profitable?

Zymeworks has a net margin of -182.75% compared to Tocagen's net margin of -176,433.34%. Zymeworks' return on equity of -23.00% beat Tocagen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zymeworks	-182.75%	-23.00%	-18.04%
Tocagen	-176,433.34%	-327.74%	-111.87%

Do institutionals & insiders hold more shares of ZYME or TOCA?

92.9% of Zymeworks shares are held by institutional investors. Comparatively, 21.4% of Tocagen shares are held by institutional investors. 1.9% of Zymeworks shares are held by company insiders. Comparatively, 10.9% of Tocagen shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Which has more volatility & risk, ZYME or TOCA?

Zymeworks has a beta of 1.17, indicating that its share price is 17% more volatile than the S&P 500. Comparatively, Tocagen has a beta of 0.01, indicating that its share price is 99% less volatile than the S&P 500.

Does the MarketBeat Community believe in ZYME or TOCA?

Zymeworks received 53 more outperform votes than Tocagen when rated by MarketBeat users. Likewise, 67.89% of users gave Zymeworks an outperform vote while only 66.03% of users gave Tocagen an outperform vote.

Company	Underperform	Outperform
Zymeworks	Outperform Votes 296 67.89%	Underperform Votes 140 32.11%
Tocagen	Outperform Votes 243 66.03%	Underperform Votes 125 33.97%

Summary

Zymeworks beats Tocagen on 15 of the 19 factors compared between the two stocks.